This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Litchfield, W. R. Articles by Dluhy, R. G. Search for Related Content PubMed PubMed Citation Articles by Litchfield, W. R. Articles by Dluhy, R. G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DEXAMETHASONE Medline Plus Health Information Steroids

Evaluation of the Dexamethasone Suppression Test for the Diagnosis of Glucocorticoid-Remediable Aldosteronism¹

Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School (W.R.L., C.C., R.G.D.), Boston, Massachusetts 02115; the Department of Medicine, New York Hospital and Cornell Medical Center (M.I.N.), New York, New York 10021; and the Departments of Medicine and Genetics, Boyer Center for Molecular Medicine (R.P.L.), Yale University School of Medicine, New Haven, Connecticut 06510

Address all correspondence and requests for reprints to: Dr. W. Reid Litchfield, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 221 Longwood Ave RFB-2, Boston, Massachusetts 02115.

Glucocorticoid-remediable aldosteronism (GRA) is a rare form of inherited hypertension caused by a characteristic gene duplication. With the advent of definitive genetic testing for GRA, the performance of the traditional screening test for GRA, the dexamethasone suppression test (DST), can be evaluated. We compared the DST to direct genetic testing in 24 patients referred for genetic screening for GRA (12 GRA positive and 12 GRA negative) based on clinical and biochemical findings, DST, and family history. Plasma aldosterone was measured before and after oral dexamethasone administration to determine the extent to which aldosterone was suppressed by glucocorticoids in each patient group. The results of the DST in these subjects were also compared to those in 19 historical patients with primary aldosteronism [4 bilateral hyperplasia and 15 aldosterone-producing adenoma (APA)] reported previously. The DST differentiated GRA-positive from GRA-negative patients with 92% sensitivity and 100% specificity. Cutoffs based on the post-DST plasma aldosterone level (<4 ng/dL) or percent suppression compared to baseline (>80%) were equally effective in correctly diagnosing GRA (only one GRA-positive patient would have been incorrectly diagnosed). However, DST in 15 APA patients revealed that 33% had greater than 80% suppression of aldosterone, and 1 had aldosterone levels below 4 ng/dL.

We conclued that a post-DST aldosterone level below 4 ng/dL will correctly diagnose GRA patients with high sensitivity and specificity. Suppression compared to baseline can be misleading, as evidenced by the results in APA patients and referred subjects who genetically screened negative.

This article has been cited by other articles:

				O. Vonend, C. Altenhenne, N. J. Buchner, G. Dekomien, C. Maser-Gluth, S. M. Weiner, L. Sellin, S. Hofebauer, J. T. Epplen, and L. C. Rump A German family with glucocorticoid-remediable aldosteronism Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1123 - 1130. [Abstract] [Full Text] [PDF]

				G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]

				C. E. Fardella, M. Pinto, L. Mosso, C. Gomez-Sanchez, J. Jalil, and J. Montero Genetic Study of Patients with Dexamethasone-Suppressible Aldosteronism without the Chimeric CYP11B1/CYP11B2 Gene J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4805 - 4807. [Abstract] [Full Text] [PDF]

				M. Stowasser, R. D Gordon, J. C Rutherford, N. Z Nikwan, N. Daunt, and G. J Slater Review: Diagnosis and management of primary aldosteronism Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 156 - 169. [PDF]

				L. Mosso, C. E. Gomez-Sanchez, M. F. Foecking, and C. Fardella Serum 18-Hydroxycortisol in Primary Aldosteronism, Hypertension, and Normotensives Hypertension, September 1, 2001; 38(3): 688 - 691. [Abstract] [Full Text] [PDF]

				C. E. Fardella, L. Mosso, C. Gómez-Sánchez, P. Cortés, J. Soto, L. Gómez, M. Pinto, A. Huete, E. Oestreicher, A. Foradori, et al. Primary Hyperaldosteronism in Essential Hypertensives: Prevalence, Biochemical Profile, and Molecular Biology J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1863 - 1867. [Abstract] [Full Text]

				Glucocorticoid-Remediable Aldosteronism J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4341 - 4344. [Full Text]

				M. Stowasser, P. R. Huggard, T. R. Rossetti, A. W. Bachmann, and R. D. Gordon Biochemical Evidence of Aldosterone Overproduction and Abnormal Regulation in Normotensive Individuals with Familial Hyperaldosteronism Type I J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4031 - 4036. [Abstract] [Full Text]

				S. R. Bornstein, C. A. Stratakis, and G. P. Chrousos Adrenocortical Tumors: Recent Advances in Basic Concepts and Clinical Management Ann Intern Med, May 4, 1999; 130(9): 759 - 771. [Abstract] [Full Text] [PDF]

				P. Mulatero, F. Veglio, C. Pilon, F. Rabbia, C. Zocchi, P. Limone, M. Boscaro, N. Sonino, and F. Fallo Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2573 - 2575. [Abstract] [Full Text]

				W. R. Litchfield, B. F. Anderson, R. J. Weiss, R. P. Lifton, and R. G. Dluhy Intracranial Aneurysm and Hemorrhagic Stroke in Glucocorticoid-remediable Aldosteronism Hypertension, January 1, 1998; 31(1): 445 - 450. [Abstract] [Full Text] [PDF]